Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Liabilities (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Total Liabilities for 4 consecutive years, with $66.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 71.36% year-over-year to $66.8 million, compared with a TTM value of $66.8 million through Sep 2025, down 71.36%, and an annual FY2024 reading of $206.4 million, down 22.04% over the prior year.
  • Total Liabilities was $66.8 million for Q3 2025 at Atara Biotherapeutics, down from $71.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $264.7 million in Q4 2023 and bottomed at $66.8 million in Q3 2025.
  • Average Total Liabilities over 4 years is $196.7 million, with a median of $228.2 million recorded in 2024.
  • The sharpest move saw Total Liabilities skyrocketed 37.09% in 2023, then tumbled 71.36% in 2025.
  • Year by year, Total Liabilities stood at $249.8 million in 2022, then grew by 5.99% to $264.7 million in 2023, then decreased by 22.04% to $206.4 million in 2024, then crashed by 67.63% to $66.8 million in 2025.
  • Business Quant data shows Total Liabilities for ATRA at $66.8 million in Q3 2025, $71.9 million in Q2 2025, and $117.1 million in Q1 2025.